- Home
- Publications
- Publication Search
- Publication Details
Title
Can we learn lessons from the FDA’s approval of aducanumab?
Authors
Keywords
-
Journal
Nature Reviews Neurology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-18
DOI
10.1038/s41582-021-00557-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
- (2021) Avi Cherla et al. JAMA Internal Medicine
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- (2021) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Aducanumab: Appropriate use recommendations
- (2021) Jeffrey Cummings et al. Alzheimers & Dementia
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
- (2021) Bruno Dubois et al. LANCET NEUROLOGY
- Landmark Alzheimer’s drug approval confounds research community
- (2021) Asher Mullard NATURE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
- (2021) Roos J. Jutten et al. NEUROLOGY
- Three FDA advisory panel members resign over approval of Alzheimer’s drug
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
- (2021) Billy Dunn et al. JAMA Internal Medicine
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
- (2019) Francesco Panza et al. Nature Reviews Neurology
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
- (2019) Bishal Gyawali et al. JAMA Internal Medicine
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
- (2019) Joshua D. Wallach et al. BMC Medicine
- Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015
- (2019) AUDREY D. ZHANG et al. MILBANK QUARTERLY
- Questions EMERGE as Biogen claims aducanumab turnaround
- (2019) Robert Howard et al. Nature Reviews Neurology
- A resurrection of aducanumab for Alzheimer's disease
- (2019) Lon Schneider LANCET NEUROLOGY
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
- (2017) Huseyin Naci et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Forward to the Past: The Case for Quantitative PET Imaging
- (2017) Adriaan A. Lammertsma JOURNAL OF NUCLEAR MEDICINE
- Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI
- (2017) Jonathan J. Darrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ASA's Statement onp-Values: Context, Process, and Purpose
- (2016) Ronald L. Wasserstein et al. AMERICAN STATISTICIAN
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
- (2016) Panagiotis Alexopoulos et al. Alzheimers Research & Therapy
- Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
- (2015) Osama Sabri et al. Alzheimers & Dementia
- Measurement of Longitudinal -Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios
- (2015) S. M. Landau et al. JOURNAL OF NUCLEAR MEDICINE
- Reporting and Grading Financial Toxicity
- (2014) Nandita Khera JOURNAL OF CLINICAL ONCOLOGY
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Epidemiology of Dementia: Alzheimer’s and Vascular Types
- (2014) Liara Rizzi et al. Biomed Research International
- Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease
- (2013) Gaël Chételat et al. NeuroImage-Clinical
- National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
- (2012) Bradley T. Hyman et al. Alzheimers & Dementia
- Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With Aβ Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue
- (2011) Seok Rye Choi et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study
- (2009) A. Okello et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now